Share:

Antiviral drug for the treatment of Covid-19 Molnupiravir (development codes MK-4482 and EIDD-2801, trade name Lagivrio[1]) is an antiviral drug that is active when taken orally. Suppresses the replication of some RNA viruses. It is used for the treatment of COVID-19 in persons infected with SARS-CoV-2[2]. This prodrug based on the synthetic nucleoside derivative N4-hydroxycytidine (also known as EIDD-1931) exhibits its antiviral effect due to the introduction of copying errors during viral RNA replication[3][4]. The drug was developed for the treatment of influenza at Emory University by the university pharmaceutical company Drug Innovation Ventures at Emory (DRIVE). It was then acquired by Ridgeback Biotherapeutics of Miami, which later entered into an agreement with Merck & Co. for further development of the drug [5]. +380 63 715-87-12